| Literature DB >> 27708549 |
Kyoung Su Sung1, Jin-Kyoung Shim1, Ji-Hyun Lee1, Se Hoon Kim2, Sohee Park3, Tae-Hoon Roh1, Ju Hyung Moon1, Eui-Hyun Kim1, Sun Ho Kim1, Su Jae Lee4, Yong Min Huh5, Seok-Gu Kang1, Jong Hee Chang1.
Abstract
BACKGROUND: A trend of stage-by-stage increase in tumorsphere (TS) formation from glioma samples has been reported. Despite this trend, not all surgical specimens give rise to TSs, even World Health Organization (WHO) grade IV gliomas. Furthermore, it has been reported that differences in overall survival of primary glioblastoma patients depends on the propensity of their tumors to form TSs. However, the weights of fresh specimens vary from one surgical isolate to the next.Entities:
Keywords: Fresh specimen; Isolation; Tumorsphere; WHO grade IV glioma; Weight
Year: 2016 PMID: 27708549 PMCID: PMC5037893 DOI: 10.1186/s12935-016-0350-1
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Demographic and clinical characteristics of patients with WHO grade IV glioma
| Characteristics | TS culture positive (n = 18) | TS culture negative (n = 17) | P value* |
|---|---|---|---|
| Age (years) | 62.6 ± 10.7 | 55.5 ± 12.9 | 0.088 |
| Sex (M:F) | 10:8 | 10:7 | 0.845 |
| Pathological diagnosis | >0.999 | ||
| GBM | 14 (77.8 %) | 15 (88.2 %) | |
| GBMO | 2 (11.1 %) | 1 (5.9 %) | |
| Gliosarcoma | 2 (11.1 %) | 1 (5.9 %) | |
| Type | >0.999 | ||
| Primary | 16 (88.9 %) | 15 (88.2 %) | |
| Recurrent | 2 (11.1 %) | 2 (11.8 %) | |
| Molecular markers | |||
| IDH1 | |||
| Wild type | 18 (100 %) | 17 (100 %) | |
| Mutation | 0 | 0 | |
| 1p19q | >0.999 | ||
| No deletion | 16 (88.9 %) | 15 (88.2 %) | |
| Codeletion | 2 (11.1 %) | 2 (11.8 %) | |
| MGMT promotor | 0.358 | ||
| Unmethylated | 10 (55.6 %) | 12 (70.6 %) | |
| Methylated | 8 (44.4 %) | 5 (29.4 %) | |
| P53 mutation | 0.443 | ||
| Wild type | 3 (16.7 %) | 5 (29.4 %) | |
| Positive by IHC | 15 (84.3 %) | 12 (70.6 %) | |
| EGFR mutation | 0.193 | ||
| Wild type | 8 (44.4 %) | 4 (23.5 %) | |
| Positive by FISH | 10 (55.6 %) | 13 (76.5 %) | |
* By Independent two-sample t test for continuous variables and Chi square test (or Fisher’s exact test) for categorical variables
Fig. 1Characterization of a representative GBM TS (TS15-88). a Morphology of TSs shown by phase-contrast microscopy (×100 original magnification). b Immunocytochemical staining of TSs for CD133 and nestin; nuclei were counterstained with DAPI (×100 original magnification). c TSs grown in neural differential media were immunostained for GFAP, MBP, NeuN, and TUBB3 (×200 original magnification). d IHC staining for CD133, CD15 and nestin in the GBM specimen from which this TS sample (TS15-88) was isolated, showing that these markers were well expressed (×200, ×400 original magnification) in this GBM specimen
Fig. 2Weight distributions of fresh specimens in the two groups. There was no significant difference in the weight of surgical samples in the two groups (P = 0.245, Mann–Whitney test)
Fig. 3Receiver-operating characteristic curve for isolation of TSs. The optimal cut-off value to maximize the sensitivity and specificity of TS isolation from WHO IV gliomas was 500 mg